FDA Inspection 1293332 — Harbin Jixianglong Biotech Co., Ltd.
The FDA completed an inspection of Harbin Jixianglong Biotech Co., Ltd. on November 7, 2025 in Haerbin. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- November 7, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Haerbin (China)